|
1
|
Rothwell PM, Fowkes FG, Belch JF, Ogawa H,
Warlow CP and Meade TW: Effect of daily aspirin on long-term risk
of death due to cancer: Analysis of individual patient data from
randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rothwell PM, Wilson M, Elwin CE, Norrving
B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on
colorectal cancer incidence and mortality: 20-year follow-up of
five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenhough A, Smartt HJ, Moore AE, Roberts
HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE2 pathway:
Key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang D and Dubois RN: Eicosanoids and
cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gustafsson A, Hansson E, Kressner U,
Nordgren S, Andersson M, Wang W, Lönnroth C and Lundholm K: EP1-4
subtype, COX and PPAR gamma receptor expression in colorectal
cancer in prediction of disease-specific mortality. Int J Cancer.
121:232–240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gustafsson A, Hansson E, Kressner U,
Nordgren S, Andersson M, Lönnroth C and Lundholm K: Prostanoid
receptor expression in colorectal cancer related to tumor stage,
differentiation and progression. Acta Oncol. 46:1107–1112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sonoshita M, Takaku K, Sasaki N, Sugimoto
Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM: Acceleration of
intestinal polyposis through prostaglandin receptor EP2 in
Apc(Delta 716) knockout mice. Nat Med. 7:1048–1051. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seno H, Oshima M, Ishikawa TO, Oshima H,
Takaku K, Chiba T, Narumiya S and Taketo MM: Cyclooxygenase 2- and
prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc
(Delta716) mouse intestinal polyps. Cancer Res. 62:506–511.
2002.PubMed/NCBI
|
|
9
|
Keith RL, Geraci MW, Nana-Sinkam SP,
Breyer RM, Hudish TM, Meyer AM, Malkinson AM and Dwyer-Nield LD:
Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected
against murine lung tumorigenesis. Anticancer Res. 26:2857–2861.
2006.PubMed/NCBI
|
|
10
|
Iresjö BM, Wang W, Nilsberth C, Andersson
M, Lönnroth C and Smedh U: Food intake, tumor growth, and weight
loss in EP2 receptor subtype knockout mice bearing PGE2-producing
tumors. Physiol Rep. 3:e124412015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma X, Aoki T, Tsuruyama T and Narumiya S:
Definition of prostaglandin E2-EP2 signals in the colon tumor
microenvironment that amplify inflammation and tumor growth. Cancer
Res. 75:2822–2832. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tilley SL, Audoly LP, Hicks EH, Kim HS,
Flannery PJ, Coffman TM and Koller BH: Reproductive failure and
reduced blood pressure in mice lacking the EP2 prostaglandin E2
receptor. J Clin Invest. 103:1539–1545. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andersson C, Gelin J, Iresjö BM and
Lundholm K: Acute-phase proteins in response to tumor growth. J
Surg Res. 55:607–614. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gelin JL, Moldawer LL, Iresjö BM and
Lundholm KG: The role of the adrenals in the acute phase response
to interleukin-1 and tumor necrosis factor-alpha. J Surg Res.
54:70–78. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lundholm K, Gelin J, Hyltander A, Lönnroth
C, Sandström R, Svaninger G, Körner U, Gülich M, Kärrefors I, Norli
B, et al: Anti-inflammatory treatment may prolong survival in
undernourished patients with metastatic solid tumors. Cancer Res.
54:5602–5606. 1994.PubMed/NCBI
|
|
16
|
Lönnroth C, Andersson M, Asting AG,
Nordgren S and Lundholm K: Preoperative low dose NSAID treatment
influences the genes for stemness, growth, invasion and metastasis
in colorectal cancer. Int J Oncol. 45:2208–2220. 2014.PubMed/NCBI
|
|
17
|
Ganesh T: Prostanoid receptor EP2 as a
therapeutic target. J Med Chem. 57:4454–4465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mutoh M, Watanabe K, Kitamura T, Shoji Y,
Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi
K, et al: Involvement of prostaglandin E receptor subtype EP(4) in
colon carcinogenesis. Cancer Res. 62:28–32. 2002.PubMed/NCBI
|
|
19
|
Brouxhon S, Konger RL, VanBuskirk J, Sheu
TJ, Ryan J, Erdle B, Almudevar A, Breyer RM, Scott G and Pentland
AP: Deletion of prostaglandin E2 EP2 receptor protects against
ultraviolet-induced carcinogenesis, but increases tumor
aggressiveness. J Invest Dermatol. 127:439–446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sung YM, He G and Fischer SM: Lack of
expression of the EP2 but not EP3 receptor for prostaglandin E2
results in suppression of skin tumor development. Cancer Res.
65:9304–9311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ansari KM, Sung YM, He G and Fischer SM:
Prostaglandin receptor EP2 is responsible for cyclooxygenase-2
induction by prostaglandin E2 in mouse skin. Carcinogenesis.
28:2063–2068. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kamiyama M, Pozzi A, Yang L, DeBusk LM,
Breyer RM and Lin PC: EP2, a receptor for PGE2, regulates tumor
angiogenesis through direct effects on endothelial cell motility
and survival. Oncogene. 25:7019–7028. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li HJ, Reinhardt F, Herschman HR and
Weinberg RA: Cancer-stimulated mesenchymal stem cells create a
carcinoma stem cell niche via prostaglandin E2 signaling. Cancer
Discov. 2:840–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YJ, Kanaji N, Wang XQ, Sato T,
Nakanishi M, Kim M, Michalski J, Nelson AJ, Farid M, Basma H, et
al: Prostaglandin E switches from a stimulator to an inhibitor of
cell migration after epithelial-to-mesenchymal transition.
Prostaglandins Other Lipid Mediat 116–117. 1–9. 2015. View Article : Google Scholar
|
|
25
|
Pino MS, Nawrocki ST, Cognetti F,
Abruzzese JL, Xiong HQ and McConkey DJ: Prostaglandin E2 drives
cyclooxygenase-2 expression via cyclic AMP response element
activation in human pancreatic cancer cells. Cancer Biol Ther.
4:1263–1269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brouxhon S, Kyrkanides S, O'Banion MK,
Johnson R, Pearce DA, Centola GM, Miller JN, McGrath KH, Erdle B,
Scott G, et al: Sequential down-regulation of E-cadherin with
squamous cell carcinoma progression: Loss of E-cadherin via a
prostaglandin E2-EP2 dependent posttranslational mechanism. Cancer
Res. 67:7654–7664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Díaz-Muñoz MD, Osma-García IC, Fresno M
and Iniguez MA: Involvement of PGE2 and the cAMP signalling pathway
in the up-regulation of COX-2 and mPGES-1 expression in
LPS-activated macrophages. Biochem J. 443:451–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liou JY, Ellent DP, Lee S, Goldsby J, Ko
BS, Matijevic N, Huang JC and Wu KK: Cyclooxygenase-2-derived
prostaglandin e2 protects mouse embryonic stem cells from
apoptosis. Stem Cells. 25:1096–1103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Niho N, Kitamura T, Takahashi M, Mutoh M,
Sato H, Matsuura M, Sugimura T and Wakabayashi K: Suppression of
azoxymethane-induced colon cancer development in rats by a
cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci.
97:1011–1014. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kitamura T, Itoh M, Noda T, Matsuura M and
Wakabayashi K: Combined effects of cyclooxygenase-1 and
cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis
in adenomatous polyposis coli gene knockout mice. Int J Cancer.
109:576–580. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fernández-Martínez AB and Lucio-Cazaña J:
Intracellular EP2 prostanoid receptor promotes cancer-related
phenotypes in PC3 cells. Cell Mol Life Sci. 72:3355–3373. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato T, Konomi K, Fujii R, Aono H, Aratani
S, Yagishita N, Araya N, Yudoh K, Beppu M, Yamano Y, et al:
Prostaglandin EP2 receptor signalling inhibits the expression of
matrix metalloproteinase 13 in human osteoarthritic chondrocytes.
Ann Rheum Dis. 70:221–226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinn JL and Chang HY: Genome regulation by
long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brosius J: Waste not, want not-transcript
excess in multicellular eukaryotes. Trends Genet. 21:287–288. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pollard KS, Salama SR, King B, Kern AD,
Dreszer T, Katzman S, Siepel A, Pedersen JS, Bejerano G, Baertsch
R, et al: Forces shaping the fastest evolving regions in the human
genome. PLoS Genet. 2:e1682006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seok J, Warren HS, Cuenca AG, Mindrinos
MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy
L, et al: Genomic responses in mouse models poorly mimic human
inflammatory diseases. Proc Natl Acad Sci USA. 110:3507–3512. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bastien L, Sawyer N, Grygorczyk R, Metters
KM and Adam M: Cloning, functional expression, and characterization
of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem.
269:11873–11877. 1994.PubMed/NCBI
|
